ASURAGEN, INC.

Basic Information

2150 WOODWARD STREET
SUITE 100
AUSTIN, TX, 78744-1038

Company Profile

n/a

Additional Details

Field Value
DUNS: 622988330
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 121


  1. IGF OT IGF BCR ABL RT QPCR TEST FOR IMPROVED MONITORING OF CML

    Amount: $1,489,494.00

    Not Available

    SBIR Phase II 2015 Department of Health and Human Services National Institutes of Health
  2. Quantitative Superplexing: Single-tube, many-target qPCR for cancer diagnostics

    Amount: $246,864.00

    DESCRIPTION provided by applicant A novel andquot Superplexandquot RT qPCR strategy will be optimized for the single tube amplification and quantification of targeted panels of fusion transcripts t ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  3. Development of a reliable and standardized molecular assay for fragile x protein

    Amount: $225,000.00

    DESCRIPTION provided by applicant The goal of this project is to develop a validated quantitative assay for the fragile X mental retardation protein FMRP to aid in the clinical management of tho ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  4. Comprehensive Solution for Transcriptome Profiling of Archived Tissues

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): The overall goal of this proposal is to expand the capability for molecular analyses of formalin fixed paraffin-embedded (FFPE) specimens through the use of whole ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Development of an information-rich assay for C9ORF72 as a test for ALS and FTD

    Amount: $222,511.00

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop, validate, and commercialize an assay to improve screening of C9ORF72, a gene on chromosome 9 that is linked to f ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. Integrated Bioinformatics Analysis Suite for targeted NGS of clinical specimens

    Amount: $1,140,126.00

    DESCRIPTION provided by applicant With the advent of rapid bench top sequencers such as the PGM and MiSeq the potential to transform cancer diagnosis and patient care is great Although sequencing ...

    SBIR Phase II 2014 Department of Health and Human Services National Institutes of Health
  7. Development of clinical triage assay for sepsis management in the Emergency Room

    Amount: $314,420.00

    DESCRIPTION (provided by applicant): The overall project objective is to further develop and clinically validate an assay, SeptiCyte(R)Triage, to improve screening and early diagnosis of conditions as ...

    SBIR Phase I 2013 Department of Health and Human Services
  8. Enabling use of blood spot cards for accurate high throughput Fragile X screening

    Amount: $2,153,865.00

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop accurate, rapid, high throughput and cost-effective screening for fragile X syndrome (FXS) and related disorders. ...

    SBIR Phase II 2013 Department of Health and Human Services
  9. SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE

    Amount: $241,044.00

    Asuragen is developing a sensitive, accurate, and reliable test (BCR-ABL1 RT-qPCR Test), for quantification of BCR-ABL1 fusion transcripts to monitor residual disease in patients with chronic myeloid ...

    SBIR Phase I 2013 Department of Health and Human Services
  10. Integrated Bioinformatics Analysis Suite for deep, targeted amplicon sequencing

    Amount: $242,940.00

    DESCRIPTION (provided by applicant): The aim of this proposal is to develop a bioinformatics pipeline, or Integrated Bioinformatics Analysis Suite (IBAS), specific for ultra-deep, targeted amplicon se ...

    SBIR Phase I 2012 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government